Dr. Ajay Kumar Duseja Hepatologist in Chandigarh

Dr. Ajay Kumar Duseja

Hepatologist, Chandigarh

MBBS, MD (Internal Medicine), DM (Gastroenterology), MNAMS, FACG

  • 1 Hospital

Specialities

  • Hepatology

  • Gastroenterology

Expertise

  • Nonalcoholic fatty liver disease (NAFLD)
  • Acute on Chronic Liver Failure
  • Viral hepatitis
  • HCC

Education

MBBS, 1988, HP University, Shimla, India

MD (Internal Medicine), 1992, HP University, Shimla, India

DM (Gastroenterology), 1996, PGIMER, Chandigarh, India

MNAMS, 2007, National Academy of Medical Sciences

FACG, 2007, American college of Gastroenterology

Practice Information

Achievements & Contributions

  • GS-US-334-0116: “A Phase 3b, Multi-center, Randomized, open label, Study to Evaluate the Safety and Efficacy of Sofosbuvir plus Ribavirin in treatment-naïve adults with chronic Genotype 1 or 3 Hepatitis C Virus Infection.
  • GS-US-334-0108: “A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg Negative, Chronic Hepatitis B.”
  • GS-US-334-0110:  Â“A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg Positive, Chronic Hepatitis B.”
  • Diabetes – Liver disease Embrace – Comprehensive action for metabolic health and wellbeing – integration of a diabetes intervention with a liver health program.
  • To study the apolipoprotein C3 (APO C3) and patatin like phospholipase domain – containing protein 3 (PNPLA3) gene polymorphism and expression in patients with nonalcoholic fatty liver disease (NAFLD).
  • A Case – Control study to investigate risk factors for Liver Cancer
  • Creation of a PGI-DILI (drug-induced liver injury) Registry
  • Expression and polymorphism of toll like receptors (TLR) and small intestinal bacterial overgrowth in patients with non-alcoholic fatty liver disease (NAFLD)
  • ICMR Award Received the prestigious ‘Dharamvir Datta Memorial Oration AwardÂ’ from the Indian Council of Medical Research for the year 2006 for research on “Nonalcoholic fatty liver disease in IndiaÂ’
  • ISG-Alkem Om Prakash Memorial Award For the year 2006 by the Indian Society of Gastroenterology- for young gastroenterologist less than 40 years of age for contribution in research and publications
  • ISG- SR Naik Memorial Award For the year 2008 by the Indian society of Gastroenterology for the best published work on nonalcoholic fatty liver disease in the year 2007-2008
  •  ISG-Zydus Oration Award (2013) For the year 2013 by the Indian Society of Gastroenterology for the research h in the area of Nonalcoholic fatty liver disease (NAFLD)
  • INASL – Plenary Award Co-author and Guide in the paper ‘Histological severity in patients with nonalcoholic fatty liver disease is related to the volume of subcutaneous adipose tissueÂ’ which received the second prize in the 19th Annual Conference of the Indian National association for the study of Liver held at PGIMER, Chandigarh in March, 2011.
  • INASL – Plenary Award Co-author and Guide in the paper ‘Increase atherosclerosis and cardiovascular disease risk in patients with nonalcoholic fatty liver diseaseÂ’ which received the third prize in the 18th Annual Conference of the Indian National association for the study of Liver held at Bhubaneswar, in March, 2010.
  • ISG-Systopic oral - Best Paper Award For the paper, ‘Insulin resistance in patients with chronic hepatitis CÂ’ in annual conference of Indian Society of Gastroenterology 2005
  • ISG- Best poster award Co-author in the best poster award for the poster, ‘Ultrastructure of mitochondria in patients with Nonalcoholic fatty liver diseaseÂ’ at the annual conference of Indian Society of Gastroenterology 2006.
  • Prize from Prize from Indian Journal of Gastroenterology for the third best original article For the paper ‘Assessment of insulin resistance and effect of metformin in nonalcoholic steatohepatitis- A preliminary reportÂ’ published in the journal in the year 2004. Duseja A, et al. Indian J Gastroenterol 2004; 23:12-15.
  • Dhiman RK, Agrawal S, Gupta T, Duseja A, Chawla Y.Chronic Liver Failure-Sequential Organ Failure Assessment is better than theAsia-Pacific Association for the Study of Liver criteria for definingacute-on-chronic liver failure and predicting outcome. World J Gastroenterol. 2014 Oct28;20(40):14934-41
  • Agrawal S, Duseja A, Gupta T, Dhiman RK, Chawla Y.SimpleOrgan Failure Count Versus Canonic Grading System for Predicting Mortality inAcute on Chronic Liver Failure. J Gastroenterol Hepatol. 2014 Sep 23
  • Umapathy S, Dhiman RK, Grover S, Duseja A, Chawla YK.Persistenceof cognitive impairment after resolution of overt hepatic encephalopathy. Am J Gastroenterol. 2014Jul;109(7):1011-9
  • Singla B, Chakraborti A, Sharma BK, Kapil S, Chawla YK, Arora SK, Das A, Dhiman RK, Duseja A. Levelsof hepatitis B virus replicative intermediate in serum samples of chronichepatitis B patients Mol Biol Rep. 2014 Jul;41(7):4689-96.
  • Duseja A, Dhiman RK, Chawla Y, Kalra N, Behera A,Gianthydatid cyst of the liver. Trop Gastroenterol. 2013 Apr-Jun; 34(2):112-3
  • Kalra N, Ahuja CK1, Duseja A, Chawla Y, Khandelwal NEndovascular management of RFA-induced hepatic arterial injury. Trop Gastroenterol. 2013 Apr-Jun;34(2):104-6
  • Guleria A, Duseja A, Kalra N, Das A, Dhiman R, Chawla Y, Bhansali A.Patients with non-alcoholic fatty liver disease (NAFLD) have an increased riskof atherosclerosis and cardiovascular disease Trop Gastroenterol. 2013 Apr-Jun; 34(2):74-82.
  • Duseja A, Chawla YK. Obesityand NAFLD: the role of bacteria and microbiota. Clin Liver Dis. 2014 Feb;18(1):59-71
  • Thumburu KK, Dhiman RK, Vasishta RK, Chakraborti A, Butterworth RF, Beauchesne E, Desjardins P, Goyal S, Sharma N, Duseja A, Chawla Y.Expression of astrocytic genes coding for proteins implicated in neuralexcitation and brain edema is altered after acute liver failure. J Neurochem. 2014 Mar;128(5):617-27
  • KalraN1, KangM, BhatiaA, Duseja AK, DhimanRK, AryaVK, RajwanshiA, ChawlaYK, KhandelwalN.Role of radiofrequency ablation in unresectable hepatocellular carcinoma: AnIndian experience. Indian J Radiol Imaging. 2013 Apr;23(2):139-44.
  • Sharma BK, Srinivasan R, Kapil S, Singla B, Chawla YK, Chakraborti A, Saini N, Duseja A, Das A, Kalra N, Dhiman RK.Angiogenic and anti-angiogenic factor gene transcript level quantitation byquantitative real time PCR in patients with hepatocellular carcinoma. Mol Biol Rep. 2013 Oct;40(10):5843-52
  • Aggarwal A, Sharma V, Vaiphei K, Duseja A, Chawla YK. Anunusual cause of cholestatic hepatitis: syphilis. Dig Dis Sci. 2013 Oct;58(10):3049-51.
  • Duseja A. What is the role of intracranial pressure monitoring in management of acute liver failure? In- 100 clinical questions in Gastroenterology. Eds Ajay Kumar, Manav Wadhavan. 2007; 17-19
  • Chawla YK, Duseja A. Extrahepatic portal venous obstruction. Tropical Hepatogastroenterology. 2008; 404-412. published by Elsevier, Reed Elsevier India Private Limited
  • Duseja A. Bacterial cholangitis. In, Gastointestinal Tract Infections. 2008; 416-24. Published by Paragon International Publishers
  • GhoshS, Duseja A. Interpretation of Liver Function Tests – INASL Text book ofLiver Diseases, 2011
  • Agrawal S, Duseja A. Mechanisms of fat accumulation and liverinjury - Elsevier ECAB, 2011
  • ChoudharyNS, Duseja A. Hepatitis B Virus  Â–Text Book of Hepato-Gastroenterology, Jaypee Brothers, 2012
  • Agrawal S, Duseja A. Nonalcoholic Fatty Liver Disease (NAFLD) -Epidemiology and Risk Factors' - Macmillan publishers [India]Group ofNature publications, 2012
  • Member – American Association for the Study of Liver (AASLD)
  • Member- National Academy of Medical Sciences (MNAMS)
  • Life member – Indian Society of Gastroenterology
  • Life member – Indian Association for the Study of liver
  • Life member – Society of Gastrointestinal Endoscopy of India
  • Life member – Indian Medical Association
-->